BMS Triple Combo Cures More than 90% of Genotypes 1a & 1b

November 8, 2013

After 12 weeks of treatment, Bristol-Myers Squibb's interferon- and ribavirin-free triple combination of daclatasvir, asunaprevir and BMS-791325 ('325) cured 92 percent of treatment-naive people with genotypes 1a or 1b of hepatitis C virus, MedPage Today reports. Gregory Everson, MD, a professor of medicine at the University of Colorado Anschutz Medical Campus in Aurora, Colorado, presented findings from a Phase IIb trial of the combination therapy at the 64th Annual Meeting of the American Association for the Study of Liver Diseases (AASLD) in Washington, DC.

The study was divided into two groups, each receiving 12 weeks of treatment: 80 participants in the first took the NS5A replication complex inhibitor daclatasvir, the NS3 protease inhibitor asunaprevir and 75 milligrams of the non-nucleoside NS5B polymerase inhibitor '325, with all of the drugs dosed at twice-a-day; 86 participants in the second group took the same regimen, but 150 mg of '325. About 10 percent of the participants in each group had cirrhosis.

A total of 91.7 percent of the higher-dose group achieved a sustained virologic response 12 weeks after completing therapy (SVR, considered a cure), as did 92.2 percent of those taking the lower dose.

The regimen proved generally well tolerated. There were two serious adverse events in the high-dose group and one in the low-dose group.

To read the study abstract, click here.

To read the MedPage Today story, click here.

© 2026 Smart + Strong All Rights Reserved.

http://beta.docker.hepmag.com/article/BMS-combo-24734-1454979965